Mangalam Drugs and Organics Limited announced its un-audited financial results for the quarter and nine months ended December 31, 2025. The company reported a total income from operations of ₹5,848.75 lakhs for the quarter. The net profit after tax for the quarter was a loss of ₹977.94 lakhs, a wider loss compared to the previous periods. For the nine months ended December 31, 2025, the total income from operations stood at ₹16,538.03 lakhs, with a net loss after tax of ₹3,075.38 lakhs.

The company's Board of Directors approved these results in a meeting held on January 15, 2026. The detailed financial results, including standalone and consolidated figures, have been published in the Financial Express and Loksatta newspapers. These results are also available on the websites of the BSE and NSE, as well as the company's website.

For the nine months ended December 31, 2025, the standalone results showed a total income of ₹16,538.03 lakhs and a net loss after tax of ₹3,075.38 lakhs. The consolidated results for the same period reported a total income of ₹16,538.03 lakhs and a net loss after tax of ₹3,086.01 lakhs. The basic and diluted EPS for the quarter ended December 31, 2025, stood at ₹(6.18) and ₹(6.18) respectively.